SLC16A2 mutation screening has therefore to be considered in males presenting with features of Pelizaeus-Merzbacher disease or X-linked spastic paraplegia,23 an allelic condition, once PLP1 mutations have been excluded. The gene discussed is PLP1; the disease is Pelizeaus-Merzbacher spectrum disorder.